Smallpox

Tonix Pharmaceuticals to Participate in BIO-Europe Digital 2021

Thursday, October 21, 2021 - 12:00pm

CHATHAM, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will deliver a Company presentation and host one-on-one meetings during the BIO-Europe 2021 event, being held virtually October 25-28, 2021.

Key Points: 
  • CHATHAM, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will deliver a Company presentation and host one-on-one meetings during the BIO-Europe 2021 event, being held virtually October 25-28, 2021.
  • Tonix reported positive efficacy data from animal studies of TNX-1800 in the first quarter of 2021 and expects to start a Phase 1 study in humans in the first half of 2022.
  • Finally, Tonix is developing TNX-21004, an in vivo diagnostic to measure the presence of functional T cell immunity to COVID-19.
  • Tonix intends to initiate a first-in-human clinical study of TNX-21004 in the fourth quarter of 2021, pending IND clearance.

Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Infectious Disease R&D Center in Maryland

Friday, October 15, 2021 - 12:00pm

CHATHAM, N.J., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it will hold a ribbon-cutting ceremony at the Company’s approximately 48,000 square foot research and development center (RDC) in Frederick, Md. on October 18, 2021 at 12:00 p.m. ET. The RDC is expected to support the Company’s expanding infectious disease pipeline. This includes providing internal capacity to discover and develop vaccines and antivirals intended to support U.S. pandemic preparedness.

Key Points: 
  • Senator for Maryland Ben Cardin and U. S. Congressman David Trone representing Marylands 6th Congressional District, are expected to speak at the event.
  • Seth Lederman, M.D., President and Chief Executive Officer of Tonix and Anthony Macaluso, PhD, Executive Vice President, Strategic Development of Tonix will make comments.
  • Marylands economy is an innovation economy, making Tonix and Frederick a great match, said U.S.
  • Tonix Pharmaceuticals does great work in the biopharmaceutical space and, equally important, brings high-paying jobs to our community said Congressman Trone.

The History of Vaccine Mandates in the US Military, States, and Public Schools Dates Back Over 200 Years, per the A-Mark Foundation

Thursday, October 14, 2021 - 1:55pm

There is also coverage of opposition to vaccine mandates throughout history, and an informative chart showing the vaccine requirements and exemptions for K-12 public schools in all 50 states.

Key Points: 
  • There is also coverage of opposition to vaccine mandates throughout history, and an informative chart showing the vaccine requirements and exemptions for K-12 public schools in all 50 states.
  • We also found that all 50 states currently require vaccinations for viruses such as polio, measles, and rubella for students in K-12 public schools."
  • While all 50 states have had mandated vaccine requirements since 1980 or earlier, there are some exemptions allowed.
  • "We hope that our report will add to available information on vaccine mandates, which should allow people to make more informed decisions about this contentious issue."

Global Vaccine Market (2021 to 2027) - by Technology Type, Indication, End-user and Geography - ResearchAndMarkets.com

Thursday, October 14, 2021 - 10:03am

However, the time taken for the development and introduction of the vaccine impedes the market growth.

Key Points: 
  • However, the time taken for the development and introduction of the vaccine impedes the market growth.
  • On the basis of technology type, the conjugate vaccine segment has the primary share in the market.
  • According to the geographical market, the market is divided into North America, Europe, Asia Pacific, and the rest of the world.
  • Thus the rising number of dreadful infectious diseases and upturn of the diseases are creating a major growth in the vaccines market.

Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference

Thursday, October 7, 2021 - 12:00pm

Fall Virtual Biotech & Specialty Pharma Conference on October 13, 2021.

Key Points: 
  • Fall Virtual Biotech & Specialty Pharma Conference on October 13, 2021.
  • analyst, Jim Molloy
    About Tonix Pharmaceuticals Holding Corp.
    Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering.
  • Finally, Tonix is developing TNX-21004, an in vivo diagnostic to measure the presence of functional T cell immunity to COVID-19.
  • Tonix intends to initiate a first-in-human clinical study of TNX-21004 in the fourth quarter of 2021, pending IND clearance.

California Pediatricians Support State-Required COVID-19 Vaccination for Eligible Children and Safe In-Person Learning

Tuesday, October 5, 2021 - 3:00pm

Pediatricians have seen first-hand the detrimental impact on education as well as physical, social, and emotional health of children with distance learning across the nation and the state of California.

Key Points: 
  • Pediatricians have seen first-hand the detrimental impact on education as well as physical, social, and emotional health of children with distance learning across the nation and the state of California.
  • AAP-CA supports the announcement by Governor Gavin Newsom to require COVID-19 vaccination for all eligible children in school as an added measure to ensure safe, in-person attendance.
  • We encourage other states to follow our lead to keep our kids safe and prevent the spread of COVID-19."
  • "We must make every effort to ensure all children and the education community are safe in our school systems," Dr. Fukuda continues.

Tonix Pharmaceuticals Announces Completion of Acquisition of Infectious Disease R&D Center in Frederick, Maryland

Monday, October 4, 2021 - 12:00pm

CHATHAM, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced it has completed the acquisition of its new research and development center (RDC) located in Frederick, Md. The approximately 48,000 square foot facility will support Tonix’s expanding infectious disease pipeline, including:

Key Points: 
  • The approximately 48,000 square foot facility will support Tonixs expanding infectious disease pipeline, including:
    Tonix purchased the RDC from Southern Research, a collaborating partner on TNX-1800 and TNX-801 development.
  • Tonix plans to make appropriate upgrades and seek certification for BSL-3 so that research may be conducted on live SARS-CoV-2- and other pathogens.
  • will complement Tonixs Advanced Development Center (ADC) being constructed in New Bedford, Mass., and its Commercial Manufacturing Center (CMC) planned in Hamilton, Mont.
  • The ADC will house laboratories dedicated to process analytical development and pilot manufacturing of the Companys vaccine candidates for clinical trials.

Tonix Pharmaceuticals Announces Oral Presentation at the American College of Rheumatology Convergence 2021

Monday, September 27, 2021 - 12:00pm

Tonix reported positive efficacy data from animal studies of TNX-1800 in the first quarter of 2021 and expects to start a Phase 1 study in humans in the first half of 2022.

Key Points: 
  • Tonix reported positive efficacy data from animal studies of TNX-1800 in the first quarter of 2021 and expects to start a Phase 1 study in humans in the first half of 2022.
  • TNX-35002 (sangivamycin) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-Investigational New Drug (IND) stage of development.
  • Finally, Tonix is developing TNX-2100, an in vivo diagnostic to measure the presence of functional T cell immunity to COVID-19.
  • Tonix intends to initiate a first-in-human clinical study of TNX-21004 in the fourth quarter of 2021, pending IND clearance.

Tonix Pharmaceuticals Expands Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

Thursday, September 23, 2021 - 12:00pm

CHATHAM, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has expanded its research collaboration with Columbia University. The research collaboration is focused on studying immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic, as well as studying in vitro T cell and antibody responses to SARS-CoV-2, the virus that causes COVID-19. The research is designed to fill in important gaps in understanding the detailed immune responses to COVID-19, and to provide a foundation for tailoring vaccines and therapeutics to appropriate individuals with precision medicine.

Key Points: 
  • CHATHAM, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has expanded its research collaboration with Columbia University.
  • The research is designed to fill in important gaps in understanding the detailed immune responses to COVID-19, and to provide a foundation for tailoring vaccines and therapeutics to appropriate individuals with precision medicine.
  • This research has the potential to lead to the isolation, characterization and cloning of therapeutically relevant fully human neutralizing monoclonal antibodies to SARS-CoV-2.
  • Such aptamers have the potential to identify biomarkers for protective CoV-2 immunity and accelerate the design of precision medicine-driven vaccines against COVID-19.

Tonix Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

Wednesday, September 22, 2021 - 12:00pm

CHATHAM, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021, at 2:00 p.m.

Key Points: 
  • CHATHAM, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021, at 2:00 p.m.
  • Investors interested in arranging a virtual meeting with the Companys management during the conference should contact the Cantor conference coordinator.
  • A webcast of the presentation will be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com .
  • About Tonix Pharmaceuticals Holding Corp.
    Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering.